Datopotamab deruxtecan in solid tumors: Recent research progress and clinical applications
Frontiers in Oncology · 07.07.2026 · 16
DOI: 10.3389/fonc.2026.1870658 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 07.07.2026. Verfasst von Ying Cao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology (III), Hangzhou Cancer Hospital, Hangzhou, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Following the approval of the first antibody-drug conjugate (ADC) for solid tumors, the therapeutic landscape in cancer has been revolutionized. Datopotamab deruxtecan (Dato-DXd) is a TROP2-targeting ADC which is composed of a humanized monoclonal antibody and a potent topoisomerase I inhibitor via a tetrapeptide-based cleavable linker. Based on data from multiple clinical trials, Dato-DXd has demonstrated compelling efficacy and a manageable safety profile. Herein, we provide an overview of recent published clinical trial data on Dato-DXd across various solid tumors. In addition, we propose future research directions to address critical issues in the clinical application of Dato-DXd, including optimal sequencing strategies with other TROP2-targeting ADCs, approaches to overcome drug resistance, and management of treatment-related adverse events.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology (III), Hangzhou Cancer Hospital, Hangzhou, China.
Zitieren
APA
Cao, Y., Mo, L. Q., Liu, Y. J., & Zhang, Z. (2026). Datopotamab deruxtecan in solid tumors: Recent research progress and clinical applications. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1870658
Vancouver
Cao Y, Mo LQ, Liu YJ, Zhang Z. Datopotamab deruxtecan in solid tumors: Recent research progress and clinical applications. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1870658
BibTeX
@article{Cao2026,
author = {Cao, Ying and Mo, Li-Qin and Liu, Ya-Juan and Zhang, Zhen},
title = {Datopotamab deruxtecan in solid tumors: Recent research progress and clinical applications},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1870658}
}
EUVIMED